Publicaciones en colaboración con investigadores/as de Hospital Universitario Quirónsalud Madrid (2)

2023

  1. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

    Frontiers in Immunology, Vol. 14

2021

  1. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

    Frontiers in Immunology, Vol. 12